Type 1 Diabetes Plasma
Powered by BiozAbout:Type 1 Diabetes Plasma — cryopreserved human plasma from IRB-consented donors with clinically confirmed type 1 diabetes, an autoimmune disease in which autoreactive T cells destroy pancreatic beta cells. Suited to C-peptide and residual beta-cell function work, cell-free DNA studies of beta-cell death, cytokine profiling and metabolomics. Donors can be stratified by islet autoantibody status, disease duration and residual C-peptide. Bulk plasma is available.
About Type 1 Diabetes Plasma
Type 1 Diabetes Plasma for Autoimmune Beta-Cell Destruction Research
Type 1 Diabetes Plasma is collected from IRB-consented donors clinically diagnosed with type 1 diabetes (T1D) and processed within one day of collection to preserve key analytes such as cytokines, proteins, and metabolites. Type 1 diabetes is an autoimmune disease: autoreactive CD8+ T cells destroy insulin-producing pancreatic beta cells, and islet autoantibodies against GAD65, IA-2, ZnT8 and insulin mark the underlying loss of tolerance. This is a mechanistically distinct condition from the insulin resistance of type 2 diabetes. Bulk plasma is available.
Why Plasma for Type 1 Diabetes Research
- C-peptide is the accepted measure of residual endogenous insulin secretion and therefore of surviving beta-cell mass. It is the primary endpoint in most beta-cell preservation trials and is readily quantified in plasma.
- Beta-cell death releases beta-cell-derived cell-free DNA into the circulation, detectable by differentially methylated insulin gene sequences. Cell-free DNA work requires plasma rather than serum, because clotting releases leukocyte genomic DNA that dilutes the signal of interest.
- Plasma supports the metabolic and inflammatory readouts that accompany autoimmune beta-cell loss, including cytokine and chemokine panels and markers of the innate response implicated in islet inflammation.
- Glucose is more stable in appropriately anticoagulated plasma than in serum left in contact with cells, which matters for any study relating glycaemia to immune or metabolic analytes in the same draw.
- Because type 1 diabetes progresses through defined preclinical stages, plasma is well suited to longitudinal designs in which the same donor supplies serial samples across changing residual beta-cell function.
- A note on matrix choice: islet autoantibody testing for GAD65, IA-2, ZnT8 and insulin is conventionally performed in serum, where the reference standardisation sits. Use the serum product for autoantibody work and plasma for C-peptide, cell-free DNA and omics studies.
Donor Stratification Available
- Islet autoantibody status and number of positive autoantibodies where tested, including GAD65, IA-2, ZnT8 and insulin autoantibodies
- Age at diagnosis and current age, including paediatric and adult-onset donors
- Disease duration, including new-onset and long-standing disease
- Residual C-peptide status where measured
- Glycaemic control by most recent HbA1c where reported
- Insulin delivery regimen: multiple daily injections, pump, or automated insulin delivery
- Comorbid autoimmune disease, including celiac disease and autoimmune thyroid disease
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed T1D donors
- Processed within one day of collection
- Anticoagulant selection available on request
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
- Longitudinal and serial collections available by request
De-identified Donor Data
- Verified T1D diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Age at diagnosis and disease duration where available
- Additional T1D-specific metadata available on request
Applications
- C-peptide measurement for residual beta-cell function research
- Cell-free DNA studies of beta-cell death and turnover
- Cytokine and chemokine profiling of islet-directed inflammation
- Biomarker discovery for disease progression and beta-cell preservation endpoints
- Metabolomic and proteomic profiling of the autoimmune diabetic state
- Pharmacodynamic support for immunotherapies aimed at preserving beta-cell mass
- Assay development and validation using disease-state plasma as a clinically relevant matrix
- Comparative profiling of type 1 against type 2 diabetes to separate autoimmune from metabolic mechanisms
Other Type 1 Diabetes Specimen Types
- Type 1 Diabetes Serum
- Type 1 Diabetes Whole Blood
- Type 1 Diabetes PBMC
- Type 1 Diabetes Leukopak
- Type 1 Diabetes Bulk Plasma
- Type 1 Diabetes CD8+ T Cells
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Type 1 diabetes plasma is available in standard and custom volumes. For pricing, availability, or to discuss a cohort stratified by autoantibody status or disease duration, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse plasma across all disease states and healthy donors, visit our human plasma page.
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Plasma are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Type 1 Diabetes Plasma with normal donor samples for comparison
Healthy Plasma
216 In Stock View InventoryNeed a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.